GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Azurity	PREVDUO	glycopyrrolate; neostigmine methylsulfate	SOLUTION;INTRAVENOUS	216903	NDA	Endo USA	42023-269-05	5 SYRINGE, PLASTIC in 1 CARTON (42023-269-05) / 3 mL in 1 SYRINGE, PLASTIC (42023-269-01)	2023-05-15
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 27, 2025

Introduction

The pharmaceuticals industry hinges on a complex and highly regulated global supply chain, particularly for essential medications like Glycopyrrolate and Neostigmine Methylsulfate. Both drugs are vital in clinical settings: Glycopyrrolate primarily manages excessive secretions and peptic ulcers, while Neostigmine Methylsulfate is crucial for reversing neuromuscular blockade post-surgery. This article provides a comprehensive overview of key suppliers, their market positions, manufacturing capacities, regulatory compliance, and strategic importance for healthcare procurement.

Glycopyrrolate Suppliers: An Overview

Manufacturers and Key Suppliers

Glycopyrrolate is a synthetic anticholinergic agent supplied by a limited number of global pharmaceutical companies due to its specialized synthesis process. Major suppliers include:

Korea United Pharm Inc.
Recognized for manufacturing both injectable and oral forms, this South Korean company supplies the drug primarily to Asian markets. Their facilities adhere to Good Manufacturing Practices (GMP) and have received approvals from the Korean Food & Drug Administration (KFDA).
Jubilant Cadista Pharmaceuticals Inc.
Based in the USA, Jubliant produces Glycopyrrolate for injectable use, focusing on North American markets. Their manufacturing facilities hold FDA approval, and the company emphasizes consistency and compliance.
Hikma Pharmaceuticals
A key European supplier, Hikma's formulations serve multiple regions, including the Middle East and Europe. Their GMP-certified facilities ensure high-quality standards and supply stability.
Argentia Healthcare
A smaller but emerging supplier, Argentia offers generic Glycopyrrolate, primarily targeting emerging markets in Latin America and Southeast Asia.

Supply Chain Dynamics

The synthesis of Glycopyrrolate involves complex steps, including chiral chemistry, making manufacturing capacity and expertise critical. Few companies possess the necessary infrastructure, creating a concentrated supply base. Regulatory approvals from agencies like the FDA, EMA, and KFDA bolster supplier credibility.

Neostigmine Methylsulfate Suppliers: An Overview

Major Producers and Distributors

Neostigmine Methylsulfate is a well-established cholinesterase inhibitor utilized widely in anesthesia and neurology. Its suppliers are comparatively more numerous due to its long history and straightforward synthesis pathways.

Sandoz (Novartis Group)
A leading global pharmaceutical producer, Sandoz provides Neostigmine Methylsulfate in various markets. Their products are GMP-compliant, with extensive distribution networks.
Mitsubishi Tanabe Pharma Corporation
A Japanese manufacturer with significant global reach, Mitsubishi offers high-purity formulations suitable for hospitals and clinics.
Sykes Laboratories
An Indian pharmaceutical manufacturer, Sykes produces generic Neostigmine Methylsulfate with a focus on the Indian subcontinent and Southeast Asia.
Vemedica
Based in the USA, Vemedica supplies both raw pharmaceutical ingredients and finished formulations, aiming for compliance with U.S. GMP standards.
Other Generics Companies
Numerous regional companies in China, India, and Eastern Europe produce Neostigmine Methylsulfate, often supplying the local or regional markets.

Supply Considerations

Neostigmine Methylsulfate enjoys broader manufacturing capacity due to its simpler synthesis. Several organizations can meet global demand, but quality and regulatory compliance remain critical factors influencing procurement decisions.

Regulatory and Quality Standards

Suppliers for both drugs must meet stringent regulatory requirements, including:

Good Manufacturing Practice (GMP) certification (FDA, EMA, PMDA, KFDA, etc.).
Pharmacopoeial compliance (USP, EP, JP) for raw materials and finished products.
Batch consistency and stability data.
Supply chain transparency and traceability guarantees.

Adherence to these standards influences global procurement decisions, especially in highly regulated markets like the USA, EU, and Japan.

Market Trends and Strategic Sourcing

Global demand for Glycopyrrolate and Neostigmine Methylsulfate remains stable, driven by their routine use in anesthesia, gastrointestinal disorders, and neurology. Suppliers with robust manufacturing capabilities and regulatory approval are prioritized for secure supply chains.

Emerging markets increasingly rely on regional generic manufacturers, which expand the supply base but raise concerns about quality assurance. Strategic partnerships, licensing agreements, and regional manufacturing hubs are prevalent to mitigate risks of shortages or disruptions.

Key Considerations for Procurement

Quality Assurance: Select suppliers with comprehensive quality certifications.
Regulatory Status: Prefer suppliers with approved manufacturing facilities in target markets.
Production Capacity: Ensure supplier capacity aligns with market demand forecasts.
Supply Chain Resilience: Diversify sources to avoid dependency on single suppliers.
Price and Cost-effectiveness: Balance cost considerations with quality and compliance.

Conclusion

The supply landscape for Glycopyrrolate and Neostigmine Methylsulfate features a select group of global and regional manufacturers. While Glycopyrrolate's specialized synthesis limits the number of suppliers, Neostigmine Methylsulfate benefits from broader manufacturing capacity. Healthcare providers and pharmaceutical companies should focus on regulatory compliance, quality standards, and supply chain resilience when engaging with suppliers, ensuring uninterrupted access to these critical medications.

Key Takeaways

Few manufacturers supply Glycopyrrolate globally, emphasizing the importance of regulatory compliance and manufacturing expertise.
Neostigmine Methylsulfate benefits from a broader supplier base; however, quality standards must be prioritized.
Regulatory certifications like GMP and pharmacopoeial compliance are critical selection criteria.
Supply chain resilience requires diversification among suppliers, especially in high-demand or emergency contexts.
Strategic partnerships and regional manufacturing can mitigate risks of shortages and ensure steady supply.

Frequently Asked Questions (FAQs)

1. Which are the top global suppliers of Glycopyrrolate?
Major suppliers include Korea United Pharm Inc., Jubilant Cadista Pharmaceuticals, Hikma Pharmaceuticals, and Argentia Healthcare. These companies have established GMP-certified manufacturing facilities serving various regional markets.

2. Is Neostigmine Methylsulfate widely available from multiple manufacturers?
Yes. Numerous regional and international manufacturers, including Sandoz (Novartis), Mitsubishi Tanabe Pharma, and Indian generics producers like Sykes Laboratories, supply Neostigmine Methylsulfate globally.

3. What regulatory certifications should suppliers possess?
Suppliers must hold GMP certification from relevant authorities (FDA, EMA, PMDA, KFDA), and their products should comply with pharmacopoeial standards (USP, EP, JP).

4. Are there regional variations in supplier availability?
Yes. Regulatory approvals and manufacturing capacities differ regionally. Developed markets often require strict compliance, favoring multinational companies, while emerging markets might rely on regional manufacturers.

5. How can healthcare providers ensure supply chain stability for these drugs?
By diversifying suppliers, establishing long-term procurement agreements, verifying regulatory and quality compliance, and maintaining strategic stockpiles to buffer against disruptions.

Sources

World Health Organization Pharmaceutical Market Data (2022).
U.S. Food and Drug Administration (FDA) Drugs Listings.
European Medicines Agency (EMA) Approvals Database.
Company Websites: Korea United Pharm Inc., Jubilant Cadista, Hikma Pharmaceuticals, Sandoz, Mitsubishi Tanabe.
Industry Reports on Generic and Specialty Drug Manufacturers.

Suppliers and packagers for generic pharmaceutical drug: GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE